Happy Tuesday Rippers fam! You might have noticed no post yesterday — we’re moving Rippers to Sundays, Tuesdays, and Thursdays to allow for more flexibility in sharing stories that are making stocks move through the week.

Our first Tuesday list has all eyes on health and biotech. Let’s dive in and see what’s moving ⬇️

🔬 Pharma giants Johnson & Johnson and Eli Lilly have both paused their coronavirus vaccine trials in the last 24 hours because of an “unexplained illness.” These two holds come after INOVIO and AstraZeneca announced clinical holds earlier in the year. These two companies later resumed their trials after clearing the illness. It’s not unusual for a pharmaceutical company to briefly stop a trial because of an unexplained illness or adverse effect. However, the haste with which these companies are pursuing a vaccine for the COVID-19 has become a cause for concern among some researchers and scientists. $JNJ fell 2% and $LLY fell 3% today. The temperamental dip in these companies might represent an opportunity to jump in.

🔬Health care service firm Accolade also made our list today, jumping nearly 8%. Accolade provides a digital platform for businesses looking to provide personalized benefits and coverage for their employees. Since going public in July, the company’s digital-first emphasis has captured a lot of attention. Public markets have welcomed a number of tele-health companies this year, fueled in part by the COVID crisis. In 2019, the company’s revenue increased 40%, moving them closer to reporting a profit in 2020. $ACCD is up 48% since IPO.

👁 There are an estimated 16 million Americans who have Dry Eye Syndrome (DES). The current DES standard of care is the prescription eye-drop RESTASIS. It’s been on the markets for years and is more prevalent since going generic. Ocular Therapeutix, a producer of a variety of eye-centric therapeutics, hopes they might offer relief to millions of Americans through a sustained-release insert for RESTASIS. $OCUL is surging 10% after announcing they have begun dosing in their new treatment.

That wraps today’s Rippers! Check back on Thursday to see more about the stocks making moves. 📈📈📈

Loading the player...
Author Profile Picture

Noah Weidner

Noah Weidner is a restless self-starter with a vehement interest in all things that make the world go around: culture, politics, economics and all the people in between. He writes the Bullish Rippers series and covers other interesting trends and happenings at Bullish.

What Did You Think?

Join The Discussion

Be the first to Comment!


Leave your comment:

Stocks Mentioned

Accolade logo

Accolade develops and provides technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits in the United States.The company offers a platform with cloud-based technology and with multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists.Its customers are primarily employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs.Accolade, Inc. was founded in 2007 and is headquartered in Plymouth Meeting, Pennsylvania. (From: StockAnalysis.com)